CAS: 1402150-32-6; (1S,2S,3R,5S)-3-((5-Amino-6-Chloro-2-(Propylthio)Pyrimidin-4-yl)Amino)-5-(2-Hydroxyethoxy)Cyclopentane-1,2-Diol
- 英文名称(1S,2S,3R,5S)-3-((5-Amino-6-Chloro-2-(Propylthio)Pyrimidin-4-yl)Amino)-5-(2-Hydroxyethoxy)Cyclopentane-1,2-Diol
- 中文名称(1S,2S,3R,5S)-3-((5-氨基-6-氯-2-(丙硫基)嘧啶-4-基)氨基)-5-(2-羟基乙氧基)环戊烷-1,2-二醇
- IUPAC名称(1S,2S,3R,5S)-3-((5-amino-6-chloro-2-(propylthio)pyrimidin-4-yl)amino)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
- 其它别名替卡格雷杂质j; (1S,2S,3R,5S)-3-((5-Amino-6-Chloro-2-(Propylthio)Pyrimidin-4-yl)Amino)-5-(2-Hydroxyethoxy)Cyclopentane-1
- CAS编号1402150-32-6
- MFCD编号:MFCD28387008
- FDA UNII编号:L6PE88Y2Z9
- 分子式:C14H23ClN4O4S分子量:378.88
- 产品CID: 621492
- 产品分类有机原料→分子砌块→芳杂环类化合物→嘧啶类化合物
相似化合物
1402150-32-6 220349-66-6 5452-43-7物理性质
MSDS等安全信息
上下游产品
4,6-dichloro-2-(propylsulfanyl)-5-pyrimidinamine ethyl 2-(6-(benzyloxycarbonylamino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy) acetate [3aS-(3aα,4α,6α,6aα)]-(tetrahydro-6-hydroxy-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl)carbamic acid phenylmethyl ester benzyl 6-(2-hydroxyethoxy)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ylcarbamate 9-[(1'R,2'S,3'S,4'S)-2',3'-dihydroxyl-4'-hydroxyethoxycyclopenta-1'-yl]-9H-2-thiopropyl-6-chloro-8-azepine ticagrelor合成工艺路线路线简述
📜4,6-二羟基-5-硝基-2-(丙基硫代)嘧啶置于铁粉,溶剂黄146,N,N-二甲基苯胺,三乙胺,三氯氧磷体系中,用 甲醇,乙醇 用作溶剂,化学反应生成替卡格雷杂质j
参考文献:基于反苯环丙胺的三唑并嘧啶类似物作为新型 Lsd1 抑制剂的设计,合成和体外/体内抗癌活性
标题:基于反苯环丙胺的三唑并嘧啶类似物作为新型 Lsd1 抑制剂的设计,合成和体外/体内抗癌活性
摘要:组蛋白赖氨酸特异性去甲基化酶 1 (Lsd1) 负责组蛋白上单/二甲基化赖氨酸残基的去甲基化.Lsd1 在许多人类疾病(如癌症)的发病机制和进展中起着广泛而重要的作用,因此正成为癌症治疗的一个有吸引力的治疗靶点.反苯环丙胺 (Tcp) 是开发不可逆 Lsd1 抑制剂的重要化学模板,代表了临床候选药物的主要化学类型.在这里,我们报告了一个新的 Tcp 衍生物池,其中三唑并嘧啶作为特殊的杂环基序.从临床上可用的抗血小板药物替格瑞洛作为命中化合物开始,我们的医学努力导致化合物9J的鉴定具有对 Lsd1 的纳摩尔抑制效力以及对肿瘤细胞的广谱抗增殖活性.酶研究表明,化合物9J对 Mao-A/b 酶具有选择性,并且还具有细胞活性,可通过抑制细胞中的 Lsd1 来提高 H3K4Me2 的表达.此外,在 H1650 异种移植小鼠模型中,以 10 和 20 Mg/kg 的低剂量口服化合物9J可以显着减小肿瘤
Doi:10.1016/j.Ejmech.2023.115321
海关参考信息
- 2905122000-异丙醇
2905310000-1,2-乙二醇
2905320000-1,2-丙二醇
2905399001-1,3-丙二醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:EP-2607355-A1
优先权日:2011-12-23
标 题:Synthesis of triazolopyrimidine compounds
权利人:LEK PHARMACEUTICALS
摘要:The present invention relates to the field of organic synthesis and describes the synthesis of specific intermediates suitable for the preparation of triazolopyrimidine compounds such as ticagrelor.
专利号:US-9278972-B2
优先权日:2011-12-23
标题 :Synthesis of triazolopyrimidine compounds
发明人：MARAS NENAD; GAZIC SMILOVIC IVANA; STERK DAMJAN
权利人:LEK PHARMACEUTICALS
摘要:The present invention relates to the field of organic synthesis and describes the synthesis of specific intermediates suitable for the preparation of triazolopyrimidine compounds such as ticagrelor.
专利号:US-9359366-B2
优先权日:2013-04-10
标 题 :Intermediate of Ticagrelor and preparation method therefor, and preparation method for Ticagrelor
发明人：SUN SHAOGUANG; SONG DEFU; HE BIAO; LAI XIAOBO
权利人:JIANGSU HENGRUI MEDICINE CO; SUNCADIA PHARMACEUTICALS CO LTD
摘要:Disclosed are intermediates of Ticagrelor and a preparation method therefor, and a preparation method for Ticagrelor. Specifically, disclosed is an intermediate, namely, a compound of Formula (VI), for preparing Ticagrelor. Further disclosed is a method for preparing the intermediate and a method for preparing Ticagrelor by using the intermediate. Ticagrelor is prepared by using the intermediate, so that the synthesis process is simple, and a defect that long reaction times under high temperature that are required in the existing methods are avoided. The method is suitable for mass production in industry, energy consumption is reduced, pollution of the environment is reduced, and discharge of waste is reduced.
专利号:CA-2859580-A1
优先权日:2011-12-23
标 题 :Synthesis of triazolopyrimidine compounds
专利号:US-2014371449-A1
优先权日:2011-12-23
标题 :Synthesis of Triazolopyrimidine Compounds
专利号:EP-2794575-A1
优先权日:2011-12-23
标题 :Synthesis of triazolopyrimidine compounds
